Immunologic study of human recombinant interleukin-2 (low dose) in patients with advanced renal cell carcinoma

This publication has 13 references indexed in Scilit:

• Augmentation of cell-mediated cytotoxicity against renal carcinoma cells by recombinant interleukin 2
  Urology, 1987
• A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 Alone
  New England Journal of Medicine, 1987
• Human lymphoblastoid interferon therapy for advanced renal cell carcinoma
  Urology, 1984
• Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells
  The Journal of Experimental Medicine, 1983
• Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.
  The Journal of Experimental Medicine, 1982
• Interleukin l and T Cell Activation
  Immunological Reviews, 1982
• Cytolytic and proliferative activity of a permanent T killer cell line
  Nature, 1979
• Monoclonal cytolytic T-cell lines.
  The Journal of Experimental Medicine, 1979
• T Cell Growth Factor: Parameters of Production and a Quantitative Microassay for Activity
  The Journal of Immunology, 1978
• Selective in Vitro Growth of T Lymphocytes from Normal Human Bone Marrows
  Science, 1976